There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
NCT06207305
Recruiting
To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Appendiceal Adenocarcinoma, Intraperitoneal Paclitaxel
Register for Updates
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
NCT06229912
Recruiting
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/12/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, HOX Gene
Register for Updates
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
NCT06018428
Recruiting
Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/12/2025
Locations: Houston, Texas, Houston, Texas
Conditions: Alopecia Areata
Register for Updates
Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study
NCT06004882
Recruiting
To compare the effects of the following types of therapy on knee range of motion when given to patients with chronic knee pain: * A standard steroid injection * Peripheral nerve stimulation (PNS) therapy in combination with a standard steroid injection * PNS therapy in combination with a placebo injection Steroid injections are given directly into the knee joints and are considered to be the standard therapy for chronic knee pain. In this study, the injection will be made of the steroid drugs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Peripheral Nerve Stimulation, Genicular Nerves, Chronic Knee Pain
Register for Updates
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
NCT06549413
Recruiting
This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Esophageal Carcinoma
Register for Updates
Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial
NCT06980025
Recruiting
This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 15 weeks gestation and continued through 36 weeks, 6 days gestation. The primary endpoint is recurrent preterm delivery or fetal death prior to 35 weeks, 0 days gestation.
Gender:
FEMALE
Ages:
14 years and above
Trial Updated:
08/12/2025
Locations: Baylor College of Medicine, Houston, Texas +1 locations
Conditions: Preterm Delivery, Obstetrical Complications
Register for Updates
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06907615
Recruiting
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: MD Anderson Cancer Hospital, Houston, Texas
Conditions: Non Small Cell Lung Cancer
Register for Updates
VK2735 for Weight Management Phase 3
NCT07104500
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #1046, Houston, Texas
Conditions: Weight Loss
Register for Updates
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
NCT06838000
Recruiting
The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and 6 to 17 YoA-years of age).
Gender:
ALL
Ages:
Between 7 months and 17 years
Trial Updated:
08/12/2025
Locations: Site # 8400001, Houston, Texas
Conditions: Pneumococcal Infections
Register for Updates
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #2046, Houston, Texas
Conditions: Weight Loss
Register for Updates
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373
Recruiting
This study is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 patients will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: VEXAS, VEXAS Syndrome
Register for Updates
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
NCT07089888
Recruiting
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2025
Locations: Pioneeer Research Solutions, Houston, Texas
Conditions: Tophaceous Gout
Register for Updates